PD-1 as a potential target in cancer therapy
Recently, an improved understanding of the molecular mechanisms governing the host response to tumors has led to the identification of checkpoint signaling pathways involved in limiting the anticancer immune response. One of the most critical checkpoint pathways responsible for mediating tumor-induc...
Main Authors: | McDermott, David F, Atkins, Michael B |
---|---|
Format: | Online |
Language: | English |
Published: |
Blackwell Science Inc
2013
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3892798/ |
Similar Items
-
Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape
by: Srivastava, Neeharika, et al.
Published: (2014) -
Targeting PD-1/PD-L1 interactions for cancer immunotherapy
by: Zitvogel, Laurence, et al.
Published: (2012) -
Targeting the PD-1/PD-L1 axis in the treatment of lung cancer
by: Matikas Alexios, et al.
Published: (2016-03-01) -
Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma
by: Yucai Wang, et al.
Published: (2018-04-01) -
Pyruvate Kinase M2: A Potential Target for Regulating Inflammation
by: Alves-Filho, Jose C., et al.
Published: (2016)